Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01115803 · ClinicalTrials.gov registry record · Phase 1
A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors
A Phase 1 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT01115803 is a Phase 1 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 29 participants.
The verdict
NCT01115803, a Phase 1 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
Study I3G-MC-JGCB (JGCB) is a multicenter, nonrandomized, open-label, dose-escalation Phase 1b study of LY2584702 in combination with either erlotinib or everolimus.
Interventions
- DRUG Everolimus
- DRUG Erlotinib
- DRUG LY2584702
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2010-03 |
| Est. Completion | 2011-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01115803
The ClinicalTrials.gov registry entry for NCT01115803 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Everolimus is the first listed.
NCT01115803 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01115803 about?
NCT01115803 is a clinical study titled "A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors". Study I3G-MC-JGCB (JGCB) is a multicenter, nonrandomized, open-label, dose-escalation Phase 1b study of LY2584702 in combination with either erlotinib or everolimus.
What is the current status of trial NCT01115803?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2010-03. Estimated completion is 2011-06.
What interventions are being tested in trial NCT01115803?
The interventions under investigation include: Everolimus (DRUG), Erlotinib (DRUG), LY2584702 (DRUG).
Who is sponsoring clinical trial NCT01115803?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.